Articles from 908 Devices

908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biomolecular analysis, today announced that GlaxoSmithKline (NYSEGSK) has purchased an additional REBEL™ cell culture media analyzer. GSK will now have a total of five REBEL analyzers being used by its biologics and vaccine process development teams.

908 Devices (NASDAQMASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it is teaming with Guardian Centers of Georgia, a world-renowned training facility that specializes in Chemical, Biological, Radiological, Nuclear, and Explosives (CBRNE) programs. Trusted by thousands of first responders, Guardian Centers of Georgia educates clientele with classroom-based courses and realistic practicum experience to identify, analyze and respond to new and evolving threats. Guardian Centers of Georgia’s use of 908 Devices MX908 has been integral to this training, particularly given the MX908’s trace detection capabilities that identify hazardous materials in real-time.

908 Devices (NASDAQMASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the forthcoming appointment of six new individuals to its Scientific Advisory Board (SAB), including Prof. Ileana Cristea, Prof. Jennifer E. Van Eyk, Prof. Anne-Claude Gingras, Prof. Jesper Olsen, Prof. Renã Robinson, and Prof. John Yates. The new SAB members join the board’s co-chairs, Christopher D. Brown, CTO 908 Devices; and J. Michael Ramsey, Scientific Founder of 908 Devices and Professor at UNC Chapel Hill, and existing members Prof. Jarrod Marto (Dana Farber Cancer Institute/Harvard Medical School) and Prof. Josh Coon (University of Wisconsin-Madison).

908 Devices (NASDAQMASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the expansion of its channel distribution network, adding new international traction and momentum. 908 Devices handheld and desktop devices are now available across six continents in more than 40 countries and configured in any of six languages.

908 Devices (NASDAQMASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced outcomes of its joint innovation partnership with Transcenta, a global biotherapeutics company. Transcenta has implemented 908 Devices’ technologies within its Process and Product Development Center and Manufacturing Facility in Hangzhou, China to facilitate their biopharma analytical workflows across large molecule characterization and formulation process development.

908 Devices (NASDAQMASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced two data analysis partnerships to integrate with the REBEL™, the first at-line fresh and spent cell media analyzer for bioprocess labs. With the integration of leading data exploratory tool Sartorius’ SIMCA® and Securecell’s Lucullus Process Information Management System (PIMS), users can seamlessly turn REBEL data into deeper actionable insights to drive operational excellence.

908 Devices (NASDAQMASS), a pioneer of purpose-built, handheld and desktop mass spectrometry devices for chemical and biomolecular analysis, has appointed Marcia Eisenberg, Ph.D., chief scientific officer of Labcorp Diagnostics, to serve on its Board of Directors effective immediately.

908 Devices (NASDAQMASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced updates to its MX908 handheld mass spec device including a first-of-its-kind aerosol module to detect and identify aerosolized chemical threats; added targets allowing responders to recognize additional priority drug substances; and activation of a Bluetooth capability to export reports and device history to Android devices. These added capabilities address gaps in responders’ workflows and speed chemical detection at the point-of-need for multiple missions.

908 Devices (NASDAQMASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the forthcoming appointment of six new individuals to its Scientific Advisory Board (SAB), including Professor Michael Betenbaugh, Dr. Tim Charlebois, Dr. Elena Chernokalskaya, Dr. John Erickson, Professor Krishnedndu Roy and Dr. Gene Schaefer. The new SAB members join the board’s co-chairs Christopher D. Brown, CTO of 908 Devices, and J. Michael Ramsey, Scientific Founder of 908 Devices and Professor at UNC Chapel Hill.

908 Devices (NASDAQMASS) and Bio-Techne Corporation NASDAQ: TECHNASDAQTECH)

908 Devices (NASDAQMASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced that Michele Fournier has joined the company as Chief People Officer. Bringing more than thirty years of global human resources experience in corporate and consulting roles, Michele will lead human resource strategies, processes, and systems to optimize business and talent outcomes for 908 Devices.

908 Devices (NASDAQMASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the U.S. Border Patrol selected the MX908® – a handheld, battery-powered, mass spectrometry device – to standardize its trace drug detection at 20 field locations across the U.S. borders, from North to South and in the Caribbean. The U.S. Border Patrol purchased more than 60 MX908 units, which are designed for rapid analysis of vapor, liquid and solid materials of unknown identity, to prevent drug smuggling and to work with local and state law enforcement in support of its counter drug mission.